A proteomic approach to identify novel disease biomarkers in LCAT deficiency

Sara Simonelli¹, Alice Ossoli¹, Cristina Banfi², Chiara Pavanello³, Laura Calabresi⁴, Elisabetta Gianazza⁵

¹Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Italy; ² Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Italy; ³ Centro Cardiologico Monzino I.R.C.C.S., Milano, Italy.

Corresponding author:
Elisabetta Gianazza
Dipartimento di Scienze Farmacologiche e Biomolecolari
Università degli Studi di Milano
via G. Balzaretti 9
I - 20133 Milano - Italia
phone +39-02-503-18362 / -18256
email elisabetta.gianazza@unimi.it

Abbreviations
apoA-I, apolipoprotein A-I;
CE, cholesteryl esters;
ELISA, enzyme-linked immunosorbent assay;
FED, fish–eye disease;
FLD, classical familial LCAT deficiency;
GGE, gel gradient electrophoresis;
HDL, high-density lipoproteins;
HDL-C, cholesterol in high-density lipoproteins;
LCAT, lecithin:cholesterol acyltransferase
LDL-C, cholesterol in low-density lipoproteins
Genetic LCAT deficiency is a rare recessive autosomal disease due to loss-of-function mutations in the gene coding for the enzyme lecithin:cholesterol acyltransferase (LCAT). Homozygous carriers are characterized by corneal opacity, haemolytic anaemia and renal disease, which represent the first cause of morbidity and mortality in these subjects. Diagnostic and prognostic markers capable of early detecting declining kidney function in these subjects are not available, and the specific serum or urine proteomic signature of LCAT deficient carriers has never been assessed. Taking advantage of a proteomic approach, we performed 2-DE analysis of carriers’ plasma and identified proteins present at different concentration in samples from homozygous carriers. Our data confirm the well-known alterations in the concentration of circulating apolipoproteins, with a statistically significant decrease of both apoA-I and apoA-II and a statistically significant increase of apoC-III. Furthermore, we observed increased level of alpha-1-antitrypsin, zinc-alpha-2-glycoprotein and retinol-binding protein 4, and reduced level of clusterin and haptoglobin. Interestingly, only beta but not alpha subunit of haptoglobin is significant reduced in homozygous subjects.

Despite the limited sample size, our findings set the basis for assessing the identified protein in a larger population and for correlating their levels with clinical markers of renal function and anaemia.

**Keywords**

LCAT deficiency; apolipoproteins; haptoglobin; haemolysis

**Significance**

This investigation defines the effects of LCAT deficiency on the level of the major plasma proteins in homozygous and heterozygous carriers. Increase for some proteins, with different function, together with a drop for haptoglobin, and specifically for haptoglobin beta chains, are reported for the first time as part of a coherent signature.

We are glad to have the opportunity to report our findings on this subject, which is one of the main interests for our research group, when Journal of Proteomics celebrates its 10th anniversary. With its various sections devoted to different areas of research, this journal is a privileged forum for publishing proteomic investigations without restrictions either in sample type or in technical approach. It is as well a privileged forum for reviewing literature data on various topics related to proteomics investigation, as colleagues in our research group have done over the years; by the way, a good share of the reviewed papers were as well reports published in Journal of Proteomics itself. The journal also offers opportunities for focused surveys through thematic issues devoted to a variety of subjects, timely selected for their current relevance in research; it was an honour for colleagues in our group to recently act as editors of one of those. Out of this diverse experience, we express our appreciation for the endeavour of
Journal of Proteomics in its first 10 years of life – and wish identical and possibly greater success for the time to come.

**Highlights**

- The plasma proteome of homozygous and heterozygous carriers of LCAT mutations were analysed.
- Decreased levels of apolipoproteins vs control subjects could be confirmed.
- The next most relevant change observed was a substantial drop in haptoglobin beta chains.
- This finding correlates with altered membrane composition and stability, haemolysis and anaemia.
- A few proteins, with diverse biological function, were found at increased levels in heterozygotes.
Human lecithin:cholesterol acyltransferase (LCAT) is a plasma glycoprotein responsible of the synthesis of most of the plasma cholesteryl esters (CE) in humans. LCAT plays a central role in the intravascular metabolism of high-density lipoprotein (HDL) and in the determination of the levels of cholesterol associated with them (HDL-C) [1]. Mutations in the LCAT gene cause two LCAT deficiency syndromes, classical familial LCAT deficiency (FLD, MIM# 245900) and fish-eye disease (FED, MIM# 136120) [2]. The differential diagnosis of FLD and FED is based on stringent biochemical criteria and is restricted to homozygotes or compound heterozygotes for these mutations. FLD cases have a completely defective cholesterol esterification; as a result, there is very little CE in plasma, and unesterified cholesterol accumulates in all plasma lipoprotein fractions. In FED cases, LCAT does not esterify cholesterol in HDL, which represent the preferred substrate of the enzyme, but does it so in VLDL and LDL: as a result, CE are present in plasma if at much reduced levels [2].

Genetic LCAT deficiency is characterized by an abnormal plasma lipoprotein profile featuring a low HDL-C level, with mainly small discoidal pre-beta particles, together with the presence of LpX, an abnormal lipoprotein usually absent in plasma and detectable only in some pathological cases [3, 4]. Carriers also present with corneal opacity due to cholesterol accumulation, mild chronic normochromic anaemia, and renal disease. Renal disease, which ultimately progresses to end-stage renal disease, is the major cause of morbidity and mortality in LCAT-deficient carriers [2]. The dramatic alterations in lipoprotein profile, especially the presence of LpX, have been shown to be directly involved in the glomerulosclerosis development [5] but the cause of kidney failure in these subjects is poorly understood.

No specific treatment for renal disease in LCAT deficiency is currently available, and carriers are usually treated symptomatically. The therapy of LCAT deficiency nephropathy mainly aims at delaying the evolution of chronic nephropathy on the basis of available therapies, such as changes in life style and diet and control of complications such as hypertension and proteinuria [2]. FLD patients are often treated by dialysis [6, 7]; they are candidates for renal transplantation, but the disease can rapidly reoccur in the transplanted tissues within a few years [8].

Not all carriers of LCAT mutations develop renal disease, and the rate of progression of renal disease is unpredictable, even within the same family; some patients rapidly worsen from a mild proteinuria to a rapid deterioration of their renal function [9]. Thus, there is the urgent need for specific diagnostic and prognostic markers, other than traditional measures of renal function, capable of detecting declining kidney function early in time in these individuals in order to address high-risk carriers toward preventive programs and potential therapies.

In this context, proteomic provides useful information for the identification and characterization of alterations in plasma protein levels. Up to now no specific serum or urine proteomic signature of LCAT deficient carriers has been defined. In this work, we applied a proteomic approach to investigate the plasma pattern in homozygous and heterozygous carriers of LCAT deficiency, in comparison with the pattern of non-affected subjects.
2. Materials and Methods

2.1. Subjects

The investigation involved a total of 38 carriers of LCAT mutations, all FLD; 13 homozygotes and 25 heterozygotes, and 23 non-affected family members (controls), all belonging to Italian LCAT-deficient families [9]. All of the subjects were fully informed of the modalities and end points of the study and signed an informed consent. Proteomic analysis of plasma was performed on samples from ten carriers, and eight age-matched controls. Five individuals were carriers of two mutant LCAT alleles (four homozygotes and one compound heterozygote, defined homozygotes throughout the paper), while five subjects were heterozygotes; all of them were diagnosed as FLD.

Blood samples were collected, after an overnight fast, into tubes containing Na$_2$-EDTA; plasma was prepared by low speed centrifugation at 4°C and stored in aliquots at -80°C until assayed.

2.2. Biochemical analyses

Plasma total and unesterified cholesterol, triglyceride and HDL-C levels were determined with standard enzymatic techniques; LDL-C was calculated with the Friedewald’s equation. Plasma apolipoprotein levels were measured by immunoturbidimetry on a Roche c311 autoanalyzer. The plasma preβ-HDL content, expressed as percentage of total plasma apolipoprotein A-I (apoA-I), was determined by native 2-DE, in which agarose gel electrophoresis was followed by nondenaturing gel gradient electrophoresis (GGE), and subsequent immunoblotting for apoA-I [10]. Plasma LCAT concentration was measured by an immunoenzymatic assay [11], and the esterification of cholesterol incorporated into an exogenous standardized substrate (LCAT activity) was measured as previously described [9]. Plasma haptoglobin levels were determined via enzyme-linked immunosorbent assay (ELISA) using the Human Haptoglobin Quantikine ELISA kit (catalogue #DHAPG0; R&D Systems, Inc., Minneapolis, USA) according to the manufacturer’s instructions.

2.3. Electrophoretic procedures

Two-dimensional electrophoresis (2-DE) maps were obtained using the immobilised pH gradient (IPG)–Dalt method, as previously described [12, 13]. Plasma (25 µL) was diluted with an equal volume of water and reduced with 2% 2-mercaptoethanol; each plasma sample was loaded at the cathodic end of one laboratory-made focusing strip. The proteins were first resolved according to charge on a non-linear pH 4-10 IPG [14] in the presence of 8 M urea and 0.5% carrier ampholytes with an anode-to-cathode distance of 8 cm. The focused proteins were then fractionated according to size by SDS-PAGE on 7.5-17.5% polyacrylamide gradients on 160x140 mm$^2$ SDS slabs using the discontinuous buffer system of Laemmli [15]. Finally, the proteins were stained with 0.3% (wt/vol) Coomassie.

The scanned gel patterns were analysed with Image Master Software (Amersham Biosciences, ver. 5.0) and the spectrometry identification of proteins, whose spot volume (i.e., absorbance integrated over area)
was statistically different among the three groups of subjects, was made as previously described [16].

For haptoglobin phenotyping, equal volumes of human plasma were diluted in sample loading buffer (1:100) and analysed as previously described [17].

Briefly, levels of haptoglobin subunits were evaluated in plasma diluted in sample loading buffer (1:100) (20 g/l sodium dodecyl sulfate, 100 ml/l glycerol, 25 mmol/l Tris [pH 6.8], 0.05 g/l bromophenol blue, 50 mmol/l dithiothreitol), and loaded on a 18% T polyacrylamide gel with Hp standards 1-1 and 2-2 (Sigma-Aldrich, Milan, Italy).

Immunoblotting was performed with a 1:10,000 dilution of polyclonal rabbit anti-human Hp (Sigma-Aldrich) and a goat anti-rabbit immunoglobulin-G horseradish peroxidase conjugated (Bio-Rad Laboratories, Milan, Italy), diluted 1:10,000 in Tris-buffered saline and Tween 20 (TBST) as secondary antibody. The bands of alpha and beta subunits (~20 kDa and ~50 kDa, respectively) were detected by ECL and quantified by densitometry using an image analysis software (QuantityOne version 4.5.2; Bio-Rad, Milan, Italy). For each subject, data are reported as the ratio of band volume, after local background subtraction, vs the volume of a normalising sample loaded in each gel, and are expressed in arbitrary units (AU). Inter-assay coefficient of variation was 12.1 ± 2.9 %.

2.4. Statistical analyses

Results are presented as mean±SD. The trends in plasma protein levels across genotypes were assessed by ANOVA; P values < 0.05 were considered as statistically significant. Statistical analysis was performed using SPSS version 24.0 software (SPSS Inc., Chicago, USA).

3. Results

3.1. Characteristics of the subjects

Individuals from the previously reported Italian families with mutations in LCAT gene participated in the study [9]. Only few subjects were submitted to a detailed two-dimensional (2-DE) proteomic investigation: in particular we analysed 5 FLD homozygotes, 5 FLD heterozygotes and 8 non-affected family members who acted as controls. Carriers of LCAT gene mutations, as previously reported, have significantly reduced HDL-C, apoA-I, apoA-II levels, and LCAT mass, with a gene-dose dependent effect. LCAT activity, as expected, was null in homozygous subjects and significantly reduced in heterozygotes while triglyceride levels, unesterified cholesterol, unesterified/total cholesterol and preβ-HDL were significantly increased (Table 1).

3.2. 2-DE analyses

The analysis of the plasma proteome of the three groups of subjects was carried out under reducing conditions with 1st dimension in the 4-10 pH range; Figure 1 shows the 2DE map of a control sample in the top panel and of a LCAT-deficient patient in the bottom panel. As expected, in most cases, we observed spot rows rather than single spots, each protein species [18] resulting from a specific set of post-
translational modifications [19, 20]. When relevant, the statistic analysis on spot volumes was made both on the values of each individual spot and of the whole spot row.

The proteins differing in volume in one or more spots, corresponding to one or more of their PTM-species or of their proteolytic fragments, in a patients vs controls comparison, are outlined in the top panel; their numbering corresponds to that of the entries in Table 2 and in Supplementary Table 1, which contain the identifications made possible by MS analysis of the picked spots. Table 2 summarizes as well the significant changes in spot abundance pointed out by the statistical treatment of the 2-DE densitometric data.

From the above comparison, significantly lower levels of apolipoprotein A-I and apolipoprotein A-II were highlighted, as expected, in homozygous subjects with respect to controls. In addition, in homozygotes, we found increased plasma levels of several proteins such as alpha-1-antitrypsin, zinc-alpha-2-glycoprotein, retinol-binding protein 4 and transthyretin, and significantly lower levels of the beta chain of haptoglobin.

3.3. Haptoglobin

Plasma haptoglobin levels were measured in a larger group of subjects that included 13 FLD homozygotes, 25 FLD heterozygotes and 23 controls (Supplementary Table 2). Plasma protein concentration both in controls and in patients was within the reported reference range (32-205 mg/dL) and the ELISA measurement did not confirm the reduction of haptoglobin concentration in homozygous subjects, observed in 2-DE analysis. Indeed, carriers of LCAT gene mutations showed plasma haptoglobin levels comparable to controls (controls 74.0 ± 27.3 mg/dL; heterozygotes, 80.8 ± 35.7 mg/dL; homozygotes, 75.7 ± 65.2 mg/dL; P for trend = 0.58).

In order to find a rationale for the above discrepancy, we investigated by immunoblotting after 1-DE the abundance of the haptoglobin subunits (alpha and beta), characterized by different molecular weights. With this approach, we observed that homozygous subjects are characterized by a significant reduction of the beta subunit (homozygotes, 0.99 ± 0.38 AU; heterozygotes, 1.43 ± 0.14 AU; controls 1.44 ± 0.22 AU; P for trend = 0.016; Figure 2) but not of the alpha subunit.

4. Discussion

The proteomic investigation we describe in this report affords for the first time a comprehensive evaluation of all major plasma components in homozygous carriers of LCAT mutations that result in the virtual absence from the circulation of the enzyme in its active form [1].

Our data on homozygous carriers fully confirm the well-known alterations in the concentration of circulating apolipoproteins, with a statistically significant decrease of both apoA-I and apoA-II and a statistically significant increase of apoC-III [21]. The main interest, however, of our approach is the indication it provides for altered concentrations of serum components other than apolipoproteins and
related to clinical manifestations of the disease, which include anaemia and renal disease. Specifically haptoglobin and clusterin decrease, while alpha-1-antitrypsin, zinc-alpha-2-glycoprotein and retinol-binding protein 4 increase in homozygous carriers.

Haptoglobin concentration is influenced by diet, and specifically by amount and composition of dietary fat: it was found significantly up-regulated in animals receiving a high-fat, high-cholesterol chow [22] whereas it was significantly down-regulated in human volunteers receiving omega-3 supplementation [23]. In more detail, haptoglobin is characterized by a molecular heterogeneity, which includes three major phenotypes: Hpt 1-1, Hpt 2-1 and Hpt 2-2. The various phenotypes perform differently in connection with lipid metabolism: when tested in in vitro and in vivo models of diabetes mellitus, reverse cholesterol transport appears much more reduced in Hp2-2 than in Hp1-1 mice [24]. The rationale for testing diabetic animals in the latter trial is that a differential prevalence of coronary heart disease – one of the sequels of altered cholesterol transport – is observed in human patients depending on haptoglobin phenotype, with opposite trend in diabetic (lower in 2-1) and in non-diabetic subjects (higher in 2-1) [25].

In our 2-DE experiments, a statistically significant decrease in homozygous vs control subjects is observed for as many as 6 spots identified as haptoglobin or better, from their position in the pl/M_ map, for haptoglobin beta chains. The finding was confirmed by an independent approach based on molecular recognition, namely immunoblotting after 1-DE separation of the proteins. On the contrary, ELISA does not distinguish the different haptoglobin subunits.

The finding of reduced circulating haptoglobin is related to normochromic haemolytic anaemia detected in FLD subject. In erythrocytes, the increase in free cholesterol and phosphatidylcholine and the decrease in phosphatidylethanolamine affect membrane fluidity; the lysis of fragile cells eventually leads to normochromic normocytic anaemia; hemoglobin is released meanwhile [26-28]. Haptoglobin binds free hemoglobin and the complex is cleared from the circulation [29]. In connection with iron homeostasis, the 2-2 phenotype is associated with lower affinity for hemoglobin and lower antioxidant capacity, which results in higher sideraemia, higher ferritin and lower transferrin concentrations, and higher transferrin saturation than in the 1-1 and 2-1 phenotypes [30].

The formation of the complex between hemoglobin and haptoglobin involves a direct contact between the alfa-beta protomer of the former and the beta chain of the latter. This was first deduced from binding experiments using either synthetic peptides [31, 32] or isolated whole subunits [33] and has been demonstrated in crystallographic experiments with both bovine [34] and human [35] proteins. It is not obvious to proceed from this evidence to our findings of a selective decrease of the circulating levels of just the beta subunits of haptoglobin, as we have evaluated both in the densitometric measurements on the spots resolved by electrophoresis and by immunoblotting. In fact, haptoglobin alpha and beta chain, bound to one another by disulfide bridges, result from the proteolytic cleavage of a single polypeptide transcript [36], which should ensure a stoichiometric synthesis. Also the mechanism of the clearance of the complex, requiring the internalization via the monocyte/macrophage scavenger receptor CD163 [37] and the transfer to early endosomes [38] implies the degradation to heme, bioactive peptides, and amino
acids, without any selectivity for either of the chain components. We could not find literature data about a varying effect on the different subunits of the condition we are considering here, hemolysis. However, Fernandez-Costa et al. report at least one example of uneven regulation of the haptoglobin chains [39]. By immunoblot on osteoarthritis patient’s sera, these authors detected an increase of the beta chain by 2.22-fold vs control subjects; instead, the alpha chain increased only by 1.4-fold when in the 1 phenotype and decreased 0.7-fold when in the 2 phenotype. While without statistical significance per se the latter result was duplicated by quantitation through the multiple reaction monitoring technology (digestion, nanoHPLC, MS).

Both haptoglobin and clusterin/apoJ, another protein changed in proteomic pattern of homozygous carriers, may be present in the circulation either in soluble form or associated with HDL. Actually, haptoglobin-related protein exists solely as a component of a minor subspecies of large high-density lipoproteins (HDL3) containing apolipoprotein L-I. Its assembly into the lipoprotein particle is mediated by the retained N-terminal signal peptide, an unusual feature for a secreted protein and the major difference between haptoglobin-related protein and haptoglobin. The 18-amino acid signal peptide interacts directly with the hydrocarbon region of lipids: lipid fluidity hastens the interaction while lipid rigidity stabilizes the association [40]. Haptoglobin is able as well to bind to lipoproteins through its interaction with apoA-I [41] and apoE [42].

Two of the three significantly increased protein in homozygous carriers, i.e. retinol-binding protein 4 and zinc-alpha-2-glycoprotein have been described altered in chronic kidney diseases. Circulating retinol-binding protein 4 appears positively correlated with serum creatinine levels and inversely correlated with glomerular filtration rates [43-46]; no correlation is observed instead with another sign of glomerular dysfunction, microalbuminuria [43], or with a different type of long-term sequel of diabetes, atherosclerosis, as assessed by carotid intima-media thickness [45]. Plasma levels of retinol-binding protein 4 decrease after kidney transplantation to patients with end-stage renal disease [46]. In carriers of genetic LCAT deficiency retinol-binding protein 4 increases in plasma with a gene-dose dependent effect.

In patients with chronic kidney disease, plasma concentration of zinc-alpha-2-glycoprotein increases with the progression of the disease and the decline of glomerular filtration rate [47]. The observation that mice (-/-) for the corresponding gene develop significantly more kidney fibrosis in models of kidney and heart injury suggests that this protein exerts an antifibrotic effect that is duplicated in vitro by sera of patients with high levels of zinc-alpha-2-glycoprotein [48]. Zinc-alpha-2-glycoprotein is significantly increased in plasma of homozygous and compound heterozygous carriers of genetic LCAT deficiency.

5. Conclusions
The concentration of any given protein at any given time in any given compartment results from the compound effects not only of synthesis and catabolism but also of distribution from/to any other compartment. The latter may be ruled solely by the physic-chemical properties of the protein or be mediated by its interaction with other proteins, to form assemblies in solution and/or receptor-ligand complexes at the cell surface. Examples of counterintuitive explanations for analytical findings are provided in routine clinical biochemistry tests by increase in circulating myoglobin due to decreased glomerular filtration and by decrease in C3 and/or C4 due to increased consumption after activation of the complement pathway(s). Changes in protein concentration independent from regulation of protein synthesis are observed also in the homozygous/doubly heterozygous carriers of LCAT mutations.

A low-grade inflammatory condition is an expected outcome in the presence of reduced levels of apoA-I (some human data: [49, 50]; some animal data: [51, 52]). The observation of increased concentration for alpha-1-antitrypsin in the homozygous/doubly heterozygous carriers of LCAT mutations confirms the expectation for its increased synthesis in these subjects. Up-regulation is to be assumed as well for haptoglobin; the finding, instead, of a lower concentration in the carriers must be caused by the overlap with a process consuming haptoglobin. Such an interfering phenomenon is easily identified in the scavenging of hemoglobin as it leaks from erythrocytes; in turn, haemolysis is the known outcome of altered membrane lipid composition in the absence of LCAT activity.

Despite the limited sample size, our finding poses the base to investigate the identified protein in a larger population and correlate them with clinical markers of the disease (renal function and anemia).

Conflict of interest

None

Acknowledgements

The authors thank Erica Gianazza for her technical support.

This work was supported in part by Telethon Italy (GGP14125 to L.C.) and by grants from MIUR Progetto Eccellenza.
Table 1
Demographic and lipid/lipoprotein profile of carriers of LCAT deficiency

<table>
<thead>
<tr>
<th></th>
<th>Carriers of LCAT deficiency</th>
<th>P trend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Controls</td>
<td>Heterozygote</td>
</tr>
<tr>
<td>N</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Sex (m/f)</td>
<td>4/4</td>
<td>3/2</td>
</tr>
<tr>
<td>Age (years)</td>
<td>36.4 ± 11.1</td>
<td>34.6 ± 12.5</td>
</tr>
<tr>
<td>Total Cholesterol (mg/dL)</td>
<td>180.1 ± 22.1</td>
<td>148.8 ± 34.1</td>
</tr>
<tr>
<td>Unesterified Cholesterol (mg/dL)</td>
<td>55.9 ± 7.3</td>
<td>50.0 ± 11.1</td>
</tr>
<tr>
<td>Unesterified/total Cholesterol</td>
<td>0.29 ± 0.02</td>
<td>0.34 ± 0.03</td>
</tr>
<tr>
<td>LDL-Cholesterol (mg/dL)</td>
<td>100.7 ± 26.3</td>
<td>78.3 ± 26.7</td>
</tr>
<tr>
<td>HDL-Cholesterol (mg/dL)</td>
<td>63.9 ± 15.6</td>
<td>43.8 ± 19.6</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>77.9 ± 45.1</td>
<td>142.0 ± 95.4</td>
</tr>
<tr>
<td>Apolipoprotein A-I (mg/dL)</td>
<td>125.4 ± 27.2</td>
<td>94.6 ± 22.1</td>
</tr>
<tr>
<td>Apolipoprotein A-II (mg/dL)</td>
<td>31.6 ± 6.4</td>
<td>28.0 ± 3.8</td>
</tr>
<tr>
<td>Apolipoprotein B (mg/dL)</td>
<td>83.1 ± 18.2</td>
<td>82 ± 24.0</td>
</tr>
<tr>
<td>preβ-HDL (% of apoA-I)</td>
<td>12.8 ± 1.7</td>
<td>19.5 ± 3.1</td>
</tr>
<tr>
<td>LCAT mass (µg/mL)</td>
<td>5.2 ± 1.7</td>
<td>3.85 ± 1.26</td>
</tr>
<tr>
<td>LCAT activity (nmol/mL/h)</td>
<td>40.3 ± 7.4</td>
<td>16.8 ± 10.3</td>
</tr>
</tbody>
</table>

Data are reported as mean±SD. nd = not detectable
Table 2
List of plasma proteins identified by MS differently expressed among groups of subjects

<table>
<thead>
<tr>
<th>Spot number</th>
<th>Protein</th>
<th>Uniprot accession #</th>
<th>Controls</th>
<th>Heterozygotes</th>
<th>Homozygotes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Alpha-1-antitrypsin</td>
<td>P01009</td>
<td>1.20 ± 0.79</td>
<td>1.28 ± 0.54</td>
<td>2.19 ± 0.92</td>
</tr>
<tr>
<td>2</td>
<td>Zinc-alpha-2-glycoprotein</td>
<td>P25311</td>
<td>0.51 ± 0.23</td>
<td>0.48 ± 0.18</td>
<td>1.05 ± 0.55</td>
</tr>
<tr>
<td>3</td>
<td>Haptoglobin</td>
<td>P00738</td>
<td>0.31 ± 0.16</td>
<td>0.22 ± 0.06</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>4</td>
<td>Haptoglobin</td>
<td>P00738</td>
<td>0.84 ± 0.34</td>
<td>0.58 ± 0.24</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>5+6+7+8</td>
<td>Haptoglobin + Serum albumin</td>
<td>P00738+P02768</td>
<td>5.37 ± 1.34</td>
<td>5.35 ± 0.77</td>
<td>3.18 ± 1.64</td>
</tr>
<tr>
<td>9</td>
<td>Complement C3</td>
<td>P01024</td>
<td>0.04 ± 0.08</td>
<td>0.36 ± 0.20#</td>
<td>0.00 ± 0.00$</td>
</tr>
<tr>
<td>10</td>
<td>Zinc-alpha-2-glycoprotein</td>
<td>P25311</td>
<td>1.12 ± 0.31</td>
<td>1.14 ± 0.30</td>
<td>1.64 ± 0.72</td>
</tr>
<tr>
<td>11</td>
<td>Zinc-alpha-2-glycoprotein or Haptoglobin</td>
<td>P25311 or P00738</td>
<td>0.30 ± 0.10</td>
<td>0.32 ± 0.14</td>
<td>1.10 ± 1.14</td>
</tr>
<tr>
<td>12</td>
<td>Clusterin</td>
<td>P10909</td>
<td>0.11 ± 0.04</td>
<td>0.13 ± 0.06</td>
<td>0.00 ± 0.00$</td>
</tr>
<tr>
<td>13</td>
<td>Apolipoprotein A-I</td>
<td>P02647</td>
<td>0.19 ± 0.08</td>
<td>0.24 ± 0.17</td>
<td>0.00 ± 0.00$</td>
</tr>
<tr>
<td>14</td>
<td>Apolipoprotein A-I</td>
<td>P02647</td>
<td>2.43 ± 0.83</td>
<td>2.00 ± 1.24</td>
<td>0.66 ± 0.68</td>
</tr>
<tr>
<td>15</td>
<td>Apolipoprotein A-I</td>
<td>P02647</td>
<td>10.03 ± 2.88</td>
<td>14.11 ± 9.39</td>
<td>4.21 ± 1.74$</td>
</tr>
<tr>
<td>16</td>
<td>Apolipoprotein A-I</td>
<td>P02647</td>
<td>0.67 ± 0.39</td>
<td>0.32 ± 0.19</td>
<td>1.17 ± 0.38$</td>
</tr>
<tr>
<td>17+18</td>
<td>Retinol-binding protein 4</td>
<td>P02753</td>
<td>0.94 ± 0.59</td>
<td>1.17 ± 0.92</td>
<td>2.17 ± 1.67</td>
</tr>
<tr>
<td>19</td>
<td>Transthyretin + Serum albumin</td>
<td>P02766+P02768</td>
<td>0.02 ± 0.04</td>
<td>0.15 ± 0.10#</td>
<td>0.00 ± 0.00</td>
</tr>
<tr>
<td>20</td>
<td>Transthyretin</td>
<td>P02766</td>
<td>0.38 ± 0.13</td>
<td>0.85 ± 0.38#</td>
<td>1.03 ± 0.40</td>
</tr>
<tr>
<td>21</td>
<td>Apolipoprotein A-II</td>
<td>P02652</td>
<td>5.95 ± 2.25</td>
<td>5.76 ± 3.15</td>
<td>0.86 ± 0.47$</td>
</tr>
</tbody>
</table>

Relative abundances, evaluated with 2DE under reducing conditions, are expressed as percent spot volume ± SD.

*P<0.05 Homozygotes vs controls; $P<0.05 Homozygotes vs heterozygotes; #P<0.05 Heterozygotes vs controls
Fig. 1. 2DE map of plasma under reducing conditions: control sample in top panel, LCAT-deficient sample in bottom panel. The first dimension is on a 4-10 non linear IPG, and the second dimension is on polyacrylamide gradient gels (7.5-17.5%). Spots selected for MS analyses are highlighted, and the entry numbers refer to Table 2 and Supplementary Table 1.
Fig. 2. Plasma β-subunit levels of haptoglobin were evaluated by immunoblotting, in carriers of LCAT gene mutations (n=5) and in non-affected family members (n=8). A representative immunoblot is shown in the top panel: M lane contains M markers, Hpt 1-1 and 2-2 lanes contain commercial samples with the corresponding phenotypes. The top panel plots the quantitative data from densitometric analysis.

Bibliography


[31] Yoshioka Y, Atassi MZ. Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r/C1s, K, and U-like protein. Proc Natl Acad Sci USA. 2004;101:14390-5.


Addendum to Materials and Methods

Mass spectrometry identification of proteins from 2-DE gels

The gel pieces were firstly washed and destained with 25 mmol/L NH₄HCO₃ and 50% v/v acetonitrile (ACN) twice, then three times with 1:2 ACN/50 mmol/L NH₄HCO₃. Finally the gel pieces were dehydrated with ACN and dried in SpeedVac for about 20 minutes.

Samples were removed from SpeedVac and trypsin (Promega, Milan, Italy) at 12 µg/ml in 50 mmol/L NH₄HCO₃ was added for 30 minutes in ice. After the trypsin absorption the gel pieces were completely covered with few microliters of 50 mmol/L NH₄HCO₃ and put overnight at 37°C. After incubation formic acid was added at a final concentration of 0.1% and the products were analyzed by mass spectrometry.

The samples were analysed by means of LC-ESI-MS/MS, with the spectra being recorded by a hybrid quadrupole orthogonal acceleration time-of-flight (Q-Tof) mass spectrometer (SYNAPT-MS G1, Waters Corporation, Milford, MA, USA) equipped with a TRIZAIC source and connected to a nanoACQUITY
UPLC system. The samples were injected onto a TRIZAIC nanoTile (Waters Corporation, Milford, MA, USA), Acquity HSS T3, that integrates a trapping column (5 µm, 180 µm x 20 mm) for desalting and an analytical column (1.8 µm, 85 µm x 100 mm) for peptide separation with an high level of reproducibility of retention time. The elution was performed at a flow rate of 450 nl/min by increasing the organic solvent concentration from 3 to 40% B in 30 min, using 0.1% formic acid in water as reversed phase solvent A and 0.1% formic acid in ACN as reversed phase solvent B. The Tof analyzer was externally calibrated using [Glu1]-fibrinopeptide B from m/z 50 to 1990, and the data were post-acquisition lock-mass corrected using the monoisotopic mass of the doubly charged precursor of [Glu1]-Fibrinopeptide B (m/z 785.8426) infused into the mass spectrometer at a flow rate of 100 nl/min through a NanoLockSpray interface using the auxiliary pump of a nanoACQUITY system. A survey scan over the m/z range of 350-1990 was used to identify protonated peptides with charge states of 2, 3 or 4, which were automatically selected for data-dependent MS/MS analysis (MassLynx v 4.1 SCN833, Waters Corporation, Milford, MA, USA). All raw MS data were processed with ProteinLynx Global SERVER software (PLGS v 2.5.3, Waters Corporation, Milford, MA, USA) and the proteins were identified by correlating the interpreted spectra with entries in UniProt database.

A UniProt database (release 2015-3; number of human sequence entries, 20199) was used for database searches of each run. Carbamidomethylation was considered as fixed modification and methionine oxidation as variable, one missed cleavage per peptide was allowed, and the mass tolerance window was set to 25 ppm for peptide precursors and 0.05 Da for fragments. In parallel, the spectra were also searched against Uniprot database using Mascot (Matrix Science, London, UK). Valid identification required two or more peptides independently matching the same protein sequence, with a significant peptide score (higher than the identity score from Mascot).
### Supplementary Table 2

Demographic and lipid/lipoprotein profile of carriers of LCAT deficiency used for serum haptoglobin determination by ELISA.

<table>
<thead>
<tr>
<th></th>
<th>Carriers of LCAT deficiency</th>
<th></th>
<th></th>
<th>P trend</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Controls</td>
<td>Heterozygote</td>
<td>Homozygotes</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>23</td>
<td>25</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Sex (m/f)</td>
<td>9/14</td>
<td>13/12</td>
<td>10/3</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>45.0 ± 26.1</td>
<td>50.5 ± 21.0</td>
<td>34.6 ± 11.2</td>
<td>0.109</td>
</tr>
<tr>
<td>Total Cholesterol (mg/dL)</td>
<td>197.1 ± 43.3</td>
<td>167.2 ± 37.2</td>
<td>160.8 ± 83.5</td>
<td>0.071</td>
</tr>
<tr>
<td>Unesterified Cholesterol (mg/dL)</td>
<td>54.3 ± 11.7</td>
<td>47.6 ± 12.5</td>
<td>143.9 ± 71.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Unesterified/total Cholesterol</td>
<td>0.28 ± 0.04</td>
<td>0.29 ± 0.06</td>
<td>0.92 ± 0.11</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL-Cholesterol (mg/dL)</td>
<td>117.8 ± 33.5</td>
<td>101.5 ± 32.5</td>
<td>95.0 ± 63.0</td>
<td>0.220</td>
</tr>
<tr>
<td>HDL-Cholesterol (mg/dL)</td>
<td>60.5 ± 14.3</td>
<td>39.6 ± 12.3</td>
<td>7.8 ± 4.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>94.7 ± 50.6</td>
<td>132.6 ± 55.3</td>
<td>279.8 ± 198.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Apolipoprotein A-I (mg/dL)</td>
<td>132.0 ± 27.7</td>
<td>103.6 ± 23.0</td>
<td>38.5 ± 9.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Apolipoprotein A-II (mg/dL)</td>
<td>31.8 ± 6.6</td>
<td>30.4 ± 5.1</td>
<td>6.7 ± 3.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Apolipoprotein B (mg/dL)</td>
<td>92.2 ± 25.3</td>
<td>93.6 ± 20.4</td>
<td>52.2 ± 30.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>preβ-HDL (% of apoA-I)</td>
<td>12.9 ± 2.9</td>
<td>18.8 ± 7.6</td>
<td>45.2 ± 10.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LCAT mass (µg/mL)</td>
<td>5.0 ± 1.0</td>
<td>3.7 ± 1.4</td>
<td>1.5 ± 1.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LCAT activity (nmol/mL/h)</td>
<td>41.1 ± 11.8</td>
<td>20.1 ± 12.3</td>
<td>nd</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are reported as mean±SD. nd = not detectable